Research
Hormonal
Simultaneous activation of GLP-1 and GIP receptors may result in synergistic and additive effects on glycemic control.
Combining therapies that target both GLP-1 and GIP receptors may improve treatment outcomes for diabetes.
StrongSupportsmedium confidence
receptoraik szimultán aktiválása a glykaemiás kontroll tekintetében – elméleti megfontolások alapján – szinergista és additív hatásokat eredményezhet.
Why this rating
Theoretical considerations are based on existing hormonal interactions.
Source
Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében
Gábor Winkler et al. · Lege Artis Medicinae · 2022
DOI 10.33616/lam.32.019
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →